Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Danavorexton - Takeda

Next Previous
Search
Drug Profile

Danavorexton - Takeda

Alternative Names: TAK-925

Latest Information Update: 10 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Takeda
  • Class Cyclohexanes; Esters; Ethers; Piperidines; Sleep disorder therapies; Small molecules; Sulfonamides
  • Mechanism of Action Orexin receptor type 2 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Narcolepsy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Neurological disorders; Respiration disorders; Sleep apnoea syndrome
  • Phase I Narcolepsy
  • No development reported Idiopathic hypersomnia

Most Recent Events

  • 10 Feb 2025 Phase-II clinical trials in Respiration disorders (unspecified route) prior to February 2025 (Takeda Pipeline, February 2025)
  • 10 Feb 2025 Takeda terminates a phase II trial in Neurological disorders (IV) due to enrollment challenges (Takeda pipeline; February 2025)
  • 30 Oct 2024 Takeda terminates a phase-II trial in Sleep apnoea syndrome in USA (IV) due to business decision unrelated to patient safety (NCT05814016)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top